Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks

American Journal of Epidemiology

Volumn 169, Issue 4, 2009, Pages 480-488

  Kapeu, Aline Simen ^a   Luostarinen, Tapio ^b   Jellum, Egil ^c   Dillner, Joakim ^d   Hakama, Matti ^b   Koskela, Pentti ^a   Lenner, Per ^e   Löve, Arthur ^f   Mahlamaki, Eija ^g   Thoresen, Steinar ^h   Tryggvadóttir, Laufey ⁱ   Wadell, Göran ^j   Youngman, Linda ^k   Lehtinen, Matti ^l  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

^c UNIVERSITY OF OSLO   (Norway)

^d LUND UNIVERSITY   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^g TAMPERE UNIVERSITY HOSPITAL   (Finland)

^h CANCER REGISTRY OF NORWAY   (Norway)

ⁱ ICELANDIC CANCER REGISTRY   (Iceland)

^j UMEÅ UNIVERSITY   (Sweden)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l UNIVERSITY OF TAMPERE   (Finland)

more..

Author keywords

Carcinoma, squamous cell; Risk factors; Smoking; Uterine cervical neoplasms

Indexed keywords

BACTERIUM ANTIBODY; COTININE; VIRUS ANTIBODY;

ANTIBODY; CANCER; CONFIDENCE INTERVAL; REPRODUCTIVE HEALTH; RISK FACTOR; SERUM; SMOKE; SMOKING; TOBACCO; VIRUS; WOMENS HEALTH;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER REGISTRY; CANCER RISK; CHLAMYDIA TRACHOMATIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FINLAND; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; ICELAND; MAJOR CLINICAL STUDY; NORWAY; RISK ASSESSMENT; RISK FACTOR; SMOKING; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHLAMYDIA TRACHOMATIS; CONFOUNDING FACTORS (EPIDEMIOLOGY); COTININE; EUROPE; FEMALE; HERPESVIRUS 2, HUMAN; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOGLOBULIN G; LOGISTIC MODELS; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; ONCOGENES; PREGNANCY; REGISTRIES; RISK FACTORS; SMOKING; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EURASIA; EUROPE; NORTHERN EUROPE; SCANDINAVIA;

CHLAMYDIA TRACHOMATIS; HUMAN HERPESVIRUS 2; HUMAN PAPILLOMAVIRUS; NICOTIANA TABACUM; PAPILLOMAVIRIDAE;

EID: 60149101938     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn354     Document Type: Article

References (48)

1. International Agency for Research on Cancer. World Cancer Report. Lyon, France: IARC Press; 2003.
2. Munoz N, Bosch XF, de Sanjose S, et al. Epidemiological classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527.
3. Lehtinen M, Luukkaala T, Wallin KL, et al. Human papillomavirus type 16 infection and risk for subsequent development of cervical neoplasia - a systematic review. J Clin Virol. 2001;19:537-539.
4. Koutsky LA, Harper DM. Chapter 13: current findings from prophylactic HPV vaccine trials. Vaccine. 2006;24(suppl 3):S114-S121.
5. Walboomers JM, Jacob MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
6. Slattery ML, Robinson LM, Schuman KL, et al. Cigarette smoking and exposure to passive smoke are risk factors for cervical cancer. JAMA. 1989;261(11):1593-1598.
7. Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control. 2003;14(9):805-814.
8. Haverkos HW, Soon G, Steckley SL, et al. Cigarette smoking and cervical cancer. Part I: a meta-analysis. Biomed Pharmacother. 2003;57(2):67-77.
9. International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118(6):1481-1495.
10. McIntyre-Seltman K, Castle PE, Guido R, et al. Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1165-1170.
11. Vineis P, Alavanja M, Buffler P, et al. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst. 2004;96(2):99-106.
12. Bramer SL, Kallungal BA. Clinical considerations in study designs that use cotinine as a biomarker. Biomarkers. 2003;8(3-4):187-203.
13. Boffetta P, Clark S, Shen M, et al. Serum cotinine level as predictor of lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1184-1188.
14. Pukkala E, Andersen A, Berglund G, et al. Nordic biological specimen banks as basis for studies of cancer causes and control - more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. Acta Oncol. 2007;46(3):286-307.
15. Tedeschi R, Bidoli E, Agren A, et al. Epidemiology of Kaposi's sarcoma herpesvirus (HHV8) in Västerbotten County, Sweden. J Med Virol. 2006;78(3):372-378.
16. Engeland A, Haldorsen T, Tretli S, et al. Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010, on the basis of relative survival analysis. A collaborative study of the five Nordic cancer registries. APMIS Suppl. 1995;49:1-161.
17. Parish S, Collins R, Peto R, et al. Cigarette smoking, tar yields, and non-fatal myocardial infarction: 14 000 cases and 32 000 controls in the United Kingdom. BMJ. 1995;311(7003):471-477.
18. Pérez-Stable EJ, Benowitz NL, Marín G. Is serum cotinine a better measure of cigarette smoking than self-report? Prev Med. 1995;24(2):171-179.
19. Murray RP, Connett JE, Lauger GG, et al. Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. Am J Public Health. 1993;83(9):1251-1257.
20. Feyerabend C, Russell MA. A rapid gas-liquid chromatographic method for the determination of cotinine and nicotine in biological fluids. J Pharm Pharmacol. 1990;42(6):450-452.
21. 125I radioimmunoassay for cotinine by selective removal of bridge antibodies. Clin Chem. 1985;31(1):118-121.
22. Clarke R, Shipley M, Lewington S, et al. Underestimations of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;150(4):341-353.
23. Cummings SR, Richard RJ. Optimum cutoff points for biochemical validation of smoking status. Am J Public Health. 1988;78(5):574-575.
24. Jarvis MJ, Feyerabend C, Bryant A, et al. Passive smoking in the home: plasma cotinine concentrations in non-smokers with smoking partners. Tob Control. 2001;10(4):368-374.
25. Dillner J, Lehtinen M, Björge T, et al. A prospective seroepidemiological study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst. 1997;89(17):1293-1299.
26. Carter J, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis. 1996;174(5):927-936.
27. Kjellberg L, Wang Z, Wiklund F, et al. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol. 1999;80(pt 2):391-398.
28. Hanna L, Keshishyan H. Chlamydial antigens stabilized with formalin for use in the microimmunofluorescence test. J Clin Microbiol. 1980;12(3):409-412.
29. Dillner J, Kallings I, Brihmer C, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis. 1996;173(6):1394-1398.
30. Lehtinen M, Koskela P, Jellum E, et al. Herpes simplex virus and risk of cervical cancer: a longitudinal, nested-case control study in the Nordic countries. Am J Epidemiol. 2002;156(8):687-692.
31. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol 1. The Analysis of Case-Control Studies. (IARC Scientific Publication no. 32). Lyon, France: International Agency for Research on Cancer; 1980.
32. Nelder JA. Intervals based on profile likelihood for GLMs. GLIM Newsl. 1990;20:25-27.
33. Lehtinen M, Luostarinen T, Youngman LD, et al. Low levels of serum vitamins A and E in blood and subsequent risk for cervical cancer: interaction with HPV seropositivity. Nutr Cancer. 1999;34(2):229-234.
34. Winkelstein W Jr. Smoking and cervical cancer of the uterine cervix: hypothesis. Am J Epidemiol. 1977;106(4):257-259.
35. Green J, Berrington de Gonzalez A, Sweetland S, et al. Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: The UK National Case-Control Study of Cervical Cancer. Br J Cancer. 2003;89(11):2078-2086.
36. Lacey JR, Frisch M, Brinton LA, et al. Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). Cancer Causes Control. 2001;12(2):153-161.
37. Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: results from a population based-study in Costa Rica. Br J Cancer. 2001;84(9):1219-1226.
38. Shields TS, Brinton LA, Burk RD, et al. A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human papillomavirus. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1574-1582.
39. Olsen AO, Dillner J, Gjøen K, et al. Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med. 1997;73(2):131-135.
40. af Geijersstam V, Kibur M, Wang Z, et al. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis. 1998;177(6):1710-1714.
41. Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer. 2000;83(11):1565-1572.
42. Gunnell AS, Tran TN, Torrång A, et al. Synergy between cigarette smoking and human papillomavirus type 16 in cervical cancer in situ development. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2141-2147.
43. Simons AM, Múgica van Herckenrode C, Rodriguez JA, et al. Demonstration of smoking-related DNA damage in cervical epithelium and correlation with human papillomavirus type 16, using exfoliated cervical cells. Br J Cancer. 1995;71(2):246-249.
44. International Agency for Research on Cancer. Tobacco Smoke and Involuntary Smoking. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol 83). Lyon, France: IARC Press; 2004.
45. Bjørge T, Hakulinen T, Engeland A, et al. A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. Cancer Res. 1997;57(18):3989-3992.
46. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous cell carcinoma of the head and neck. N Engl J Med. 2001;344(15):1125-1131.
47. KB through STAT1/IRF-1 pathways. J Biol Chem. 2001;276(16):13153-13159.
48. Poppe WA, Ide PS, Drijkoningen MP, et al. Tobacco smoking impairs the local immunosurveillance in the uterine cervix. Gynecol Obstet Invest. 1995;39(1):34-38.